Evidence map›Paper›PMID 41568380›Full record

ArticleFrontiers in oncology2025

Case Report: A rare case of synchronous ovarian mixed germ cell tumor and mast cell leukemia in a pediatric patient.

Chengzhu Liu, Jinhua Chu, Yang Wan, Huiping Wang, Hongzhen Yu, Kunlong Zhang, Zhiwei Xie, Songji Tu, Ningling Wang, Linhai Yang

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chengzhu LiuDepartment of Hematology and Oncology in Pediatric, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Jinhua ChuDepartment of Hematology and Oncology in Pediatric, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Yang WanDepartment of the Hematologic Disease Diagnosis and Treatment Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Huiping WangDepartment of the Hematologic Disease Diagnosis and Treatment Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Hongzhen YuDepartment of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Kunlong ZhangDepartment of Hematology and Oncology in Pediatric, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhiwei XieDepartment of Hematology and Oncology in Pediatric, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Songji TuDepartment of Hematology and Oncology in Pediatric, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Ningling WangDepartment of Hematology and Oncology in Pediatric, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Linhai YangDepartment of Hematology and Oncology in Pediatric, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with concurrent malignancies pose significant diagnostic and therapeutic challenges. We report a rare and fatal case of synchronous ovarian mixed germ cell tumor and mast cell leukemia (MCL) in a 13-year-old female, characterized by a shared clonal origin. The patient initially presented with a large pelvic mass, elevated alpha-fetoprotein(AFP) and human chorionic gonadotropin (β-HCG), anemia, and thrombocytopenia. Exploratory laparotomy confirmed a diagnosis of mixed germ cell tumor, predominantly dysgerminoma with a minor choriocarcinoma component. Despite an initial decrease in serum tumor markers to platinum-based chemotherapy, persistent cytopenias and bone marrow infiltration raised concern for hematologic malignancy. Genomic analyses of both ovarian tumor and bone marrow samples identified identical somatic mutations, including KIT D816V, NRAS G12C and TP53 Y220C, strongly suggesting a common progenitor. Subsequent immunophenotyping, histology, and transcriptome sequencing confirmed the diagnosis of concurrent mast cell leukemia. Targeted therapy with avapritinib and ruxolitinib was initiated but yielded limited response. Further salvage therapy failed due to disease progression and treatment intolerance, and the patient succumbed to multiple organ failure. This case underscores the clinical and genetic overlap between germ cell tumors and hematological malignancies in pediatric patients, highlighting the role of KIT mutations as a potential unifying driver. Given the consistent co-occurrence of KIT mutations in previously reported similar cases, we propose the recognition of a distinct disease entity: ovarian germ cell tumor/mastocytosis with KIT mutations. This report emphasizes the importance of early genetic profiling and multidisciplinary collaboration in diagnosing and managing rare, genetically unified malignancies in pediatric oncology.

Indexed as

germ cell tumorKIT D816Vmast cell leukemiapediatricsystemic mastocytosis

Identifiers

PMID41568380
PMCPMC12815785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.